title: Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
abstract: Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.
authors: Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors: Patrick
authors: P
authors: Oellers
authors: Aaron
authors: A
authors: Savar
authors: Felipe
authors: F
authors: Samaniego
authors: Barbara
authors: B
authors: Pro
authors: Bita
authors: B
authors: Esmaeli
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000175:diagnosis / Q000532:radiotherapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D019788:Fluorodeoxyglucose F18; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000532:radiotherapy*; D008297:Male; D049268:Positron-Emission Tomography; D000069283:Rituximab; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015021:Yttrium Radioisotopes; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; C422802:ibritumomab tiuxetan